The grant, plainly. On August 24, 2021, The General Hospital Corporation was issued US11098326B2, covering the use of RNA-guided FokI nucleases to increase specificity for genome editing. The CPC tags — C12N 9/22 (nucleases), C12N 15/102, and the C07K 2319 fusion-protein series — describe an engineering approach to reduce off-target editing, a central safety and value question for the field.
Why a financing desk cares: gene-editing platforms run years of cash burn before any product revenue, and their valuations rest on the strength of the editing IP they own or license. Specificity — reducing off-target effects — is one of the most commercially important problems in the field, so IP that improves it is a high-value intangible on a pre-revenue balance sheet.
The cautionary read: a specificity grant strengthens the platform story but does not change the runway arithmetic. Cash divided by burn still sets the clock. For holders, the relevant question is whether successive financings buy enough quarters to turn specificity IP into clinical and then commercial value.
What the grant does not show: the licensee's cash, burn, or dilution history. Those come from corporate filings, not the patent. The grant establishes that the specificity IP exists and what it claims.
The takeaway: treat specificity-improving editing grants as premium intangibles behind a pre-revenue platform, then run the runway math from the filings. This August 2021 FokI-nuclease grant is a dated example of the kind of IP that carries a gene-editing balance sheet.